A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants
NCT ID: NCT05036512
Last Updated: 2023-07-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
129 participants
INTERVENTIONAL
2020-12-09
2023-02-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)
NCT04983264
A GBT021601 ADME Microtracer Study in Healthy Volunteers
NCT05718687
GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)
NCT05632354
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
NCT06546670
A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients
NCT03815695
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo as a tablet or capsule with dose based off of preceding cohort's data.
GBT021601
Administered orally with water as a single dose in the morning.
GBT021601
GBT021601 as a tablet or capsule with dose based off of preceding cohort's data.
GBT021601
Administered orally with water as a single dose in the morning.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GBT021601
Administered orally with water as a single dose in the morning.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index ≥ 18.0 to ≤ 30.0 kg/m2
* Body weight ≥ 50 kg at screening and Day -1
Exclusion Criteria
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ICON Early Phase Services, LLC
San Antonio, Texas, United States
Harry Perkins Institute of Medical Research
Nedlands, Western Australia, Australia
Linear Clinical Research
Nedlands, Western Australia, Australia
Oxford Compounding
North Perth, Western Australia, Australia
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C5351001
Identifier Type: OTHER
Identifier Source: secondary_id
GBT021601-011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.